Keys to successful lentiviral vector scale-up

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Keys to successful lentiviral vector scale-up

With lentiviral vectors (LVV) set to play a prominent role in the futures of both ex vivo and in vivo gene therapy, ensuring successful production scale-up whilst maintaining product quality and yield has become a pressing challenge for industry.

This webinar will take attendees on a journey through the scale-up of a LVV process from shake flasks to 50 L single-use bioreactor where comparable titers, cell viability, and vector quality were maintained throughout. A case study from Cyto-Facto will provide real-world learnings regarding proven parameters, workflows, and system configurations that align with regulatory expectations and support the seamless transition to clinical and commercial scales.

In addition, side-by-side data comparing yield recovery, turbidity reduction, and processing time for depth filtration versus continuous flow centrifugation + filtration methods of clarification will be presented, helping you choose the most efficient clarification setup for your own workflow.

Attend this webinar to:

Understand how to optimize and control key upstream processes parameters during seed train, transfection, and production to improve LVV process performance and reproducibility at scale
Prepare for clinical and commercial readiness: overcome challenges in translating small-scale LVV production to larger volumes with proven, data-backed approaches
Boost process performance and cost-effectiveness through strategies that reduce consumable costs and processing time – critical for scale up and GMP operations
Gain expert insight into a process tech transfer

Jonathan Zmuda, PhD

Senior Director, Cell Biology R&D at Thermo Fisher Scientific

Jonathan Zmuda, Ph.D. is a Senior Director of Cell Biology R&D at Thermo Fisher Scientific located in Frederick, MD (USA). Dr. Zmuda leads a team of scientists dedicated to developing new products for applications including transient protein expression, viral vector production and nucleic acid delivery. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his BSc degree from Dickinson College in Carlisle, PA.

Shin Kawamata, PhD

Senior Advisor, Viral Vector CDMO business at Cyto-Facto Inc.

Dr. Shin Kawamata is a physician–scientist with decades of experience advancing cell and gene therapy. After earning his M.D. and Ph.D. in Japan and completing postdoctoral research at Systemix and Stanford, he joined the Foundation for Biomedical Research and Innovation (FBRI) at Kobe, eventually becoming Director of its Center for Cell Therapy. He later served as CEO of Cyto-Facto Inc., where he helped establish Japan’s first commercial GMP manufacturing site for Novartis’ CAR-T therapy Kymriah®. Now a Senior Advisor, he leads Cyto-Facto’s viral vector CDMO initiative while also serving in key ISCT leadership roles and as a Specially Appointed Professor at Kobe University, where he continues to advance iPSC, MSC and CGT biomanufacturing.

in 49

Days

You have registered for this webinar